Website

Bio

Fiona has over 25 years experience in healthcare, biotechnology and venture capital. She was the co-founder and Chief Executive of the anti-infectives company Novacta Biosystems until the end of 2007. Before this Fiona was Chief Executive of Pharminox Limited, Novarticulate BV and Metris Therapeutics Limited. She worked in venture capital for Rothschilds and J&J Development Corporation in the mid-90s specialising in the strategic development and management of early-stage companies. Fiona’s early career was in business development at CRC Technology Limited and at Celltech plc.

Sessions

Facebook Linkin Twitter Website

Bio

After a 30-year stint as a professional editor and journalist that ended on April 30, 2016, Mr Narayanan Suresh formally joined ABLE on May 2, 2016 as its COO. The association was founded in 2003 to represent the interests of the fast-growing biotechnology industry.

For more than 13 years as the Editor of BioSpectrum, Mr N Suresh has worked closely with the biotech sector. Therefore, his rich experience and knowledge are expected to benefit the industry in due course of time. From being  a neutral observer to the biotech industry insider, his second innings now allows him to continue the association with sector.

The journalistic journey of Mr N Suresh began exactly 30 years ago in May 1996 when he joined the Times of India in New Delhi as their first-ever Exclusive Science Reporter, after a grueling 10-month training in Social Journalism with the Times Center for Media Studies( then called The Times Research Foundation School for Social Journalism) in the very first batch.

From a writer, in 1997 he moved to CyberMedia as the Associate Editor of DATAQUEST, the country’s leading IT publication, and it was a transformation, from being just a writer to an Editor-Manager. “The Chairman of Cybermedia, Mr Pradeep Gupta as well as one of its then Directors, Mr Shyam Malhotra believed in my capabilities and gave me many challenging roles that involved creating strong publication brands, says Suresh nostalgically.

At CyberMedia, he was later involved in launching and building the BioSpectrum magazine, the only source of information for biotech industry back then. Later, he also moved on with the brand to MM Activ Sci-Tech Communications when it was acquired by the later. During his long stint as the Editor, he managed and edited various publications within these publishing houses.

Sessions

Linkin Website

Bio

Dr James Wilkie is Director of Enterprise & Innovation for the University of Birmingham, CEO for Alta Innovations (the technology transfer company for the University of Birmingham), and CEO of the Birmingham Research Park, which houses two incubators including the BioHub Birmingham®, a fully equipped life sciences incubator.

Sessions

Linkin Twitter Website

Bio

Prabhu Mishra , CEO & Founder- StemGenn Therapeutics, President – StemMax Research & Therapeutics Pvt Ltd. Co-Founder- Global StemGenn Therapy & Research PVT ltd. Ex- Secretary General – Stem cell society (India) , Founder President – Anti ageing Foundation, Vice President- Indian Stem cell study Group.

Advisor: Regenerative Therapy- IORA, Stem cell committee Head – ISAR Delhi Chapter , Reviewer – Journal of cutaneous and aesthetic surgery. Associate Editor – Indian journal of stem cell Therapy. Collaborator with SumanDeep Vidyapeeth University , InDNA LIFESCIENCES. Member ,International society of Cellular Therapy, American society of cell and Gene Therapy, International society of stem cell Research. Founded- Indian Regenerative and Aesthetic science study group.

Given consultation to more than 15 stem cell facilities. Prabhu Mishra have set up 8 stem cells centre across country and Internationally.

Prabhu Mishra, welcomes you to StemGenn Therapeutics, a leading stem cell therapy & regenerative medicine services company, hurling the stem cell revolution in India. It is dedicated to the development and commercialisation of cellular therapies and stem cell research in India. Prabhu Mishra works to develop strategic alliances and to implement national and international projects for the mission of advancing regenerative medicine and stem cell therapy.

StemGenn Mission is contribute to human health by enabling technologies using Regenerative Medicine. Aims to provide treatment option in Aesthetic Medicine, Anti Ageing , Infertility, Cosmetic Gynaecology , Wellness , Life style Diseases & Auto immune diseases.

StemGenn started world class training module in Stem Cell & Regenerative Medicine , Bio Identical Hormones , Aesthetic Medicine , Cosmetic Gynaecology & Anti Ageing .

Prabhu Mishra works to develop strategic alliances and to implement national and international projects for the mission of advancing regenerative medicine and stem cell therapy. Prabhu’s personal experience with life-changing cellular therapies and adult stem cell transplant programme ignited his passion to be involved with an innovative new area of medicine bringing together the industry leaders in regulatory, science, medicine, safety and ethics via a association model to yield the best possible patient outcomes.
 Prabhu participates in the organizational business strategy, membership procurement, marketing, international and domestic conference and event planning/implementation, financial decisions and budgeting. Prabhu works with the GIOSTAR team to develop compelling business plans to optimize strategy, present a competitive edge, and to articulate the client’s competitive position. Prabhu creates financial reports for Executive Summaries such as profit/loss statements which include sales forecasts, personnel and operating costs, break even analysis and cash flow projections.

Specialties Area: Blood Bank & Transfusion Medicine , Cord blood Banking, Stem cells (adipose, dental pulp, peripheral blood, limbal) Plastic Surgery, General Surgery(Abdominal Wall Reconstruction, Hernia Repair, Breast Surgery, Wound Care and Trauma), Orthopedics, Spine , Sports Medicine, Neurosurgery, Trauma, Colon Rectal, Cardiac, Perfusion, Dental, Oral Max , Vascular, BMA, Bone Marrow Aspirate, PRP, Platelet Rich Plasma, Stem Cell, Tissue Regeneration and Regenerative Medicine.

Sessions

Linkin Website

Bio

Professor S.S. Vasan is a Senior Business Development Manager (Research & Technical Microbiology Services & Innovation) in a new executive agency of the Department of Health, formed by the merger of Health Protection Agency with ~100 sender organisations such as National Treatment Agency, Public Health Observatories, UK National Screening Committee and NHS cancer and non-cancer screening programmes, Cancer Registries, Quality Assurance Reference Centres, Strategic Health Authorities, Specialised Commissioners, and parts of the Department of Health, including Public Health Marketing.

It aims to help bring about fundamental improvements in the public’s health and wellbeing by focusing its energies on five key priorities:

1. helping people to live longer by reducing preventable deaths from conditions such as heart disease, stroke, cancer and liver disease

2. increasing healthy life expectancy by tackling conditions which place a burden on many lives, such as anxiety, depression and back pain

3. protecting the population from infectious diseases and environmental hazards, including emerging risks and the growing problem of antimicrobial resistance

4. supporting families to give children the best start in life, through working with health visitors, Family Nurse Partnerships and the Troubled Families Programme

5. helping employers to facilitate and encourage their staff to make healthy choices.

Over the last two decades, I have gained expertise and experience in these areas:
– Biosafety, biodefence and biosecurity
– Biotechnology and bioengineerng
– GMOs, and their applications in health and agriculture
– Infectious diseases, especially medical entomology
– Microbiology services including bioprocessing and bioseparation
– New business development and innovation, especially for life sciences, bio/pharma and medical products.

Sessions

Website

Bio

Hitesh Thakrar is a Partner of Syncona Investment Management Ltd. He is an experienced investor in the sector, having spent over 20 years investing in public global equities in the life sciences, technology and the innovation sectors.

He has worked at various institutions in equity research and Fund Management from ADIA, the sovereign wealth Fund of Abu Dhabi, JP Morgan, Aviva Group, Dresdner Bank and New Star Asset Management. He has a strong track record, rated AA manager and was also a top 1 percentile manager in global equities. He is on the Board of Desktop Genetics, a CRISPR IP library company, backed by Illumina and is an angel investor in early stage Innovation companies. He is also on the Investment Committee of the LBA Scale Up Innovation Fund.

Hitesh holds a degree in Chemistry from Kings College, London, MBA from Cranfield University and CFA, the American Association of Investment Analysts.

Sessions

Website

Bio

Andrew Fried is IBM Life Sciences Leader for Europe.

Andrew helps clients address industry imperatives and save lives through the power of cognitive insights.  He works with clients to advance the next generation of discovery and development, acting on insights to drive value, enhance relationships across the ecosystem and empowering people to make better decisions.

Prior to transferring to Europe in July 2015, Andrew was IBM’s Life Sciences Leader for China. While in China Andrew worked with many leading multi-national companies and several Chinese Life Sciences companies who were leaders in their respective segment.

Before joining IBM in 2000, Andrew had a successful 14-year career with a leading strategy consulting company.  He graduated from Melbourne University with a Bachelor of Arts, and Monash University (Melbourne, Australia) with a Bachelor of Business.  Andrew has a Masters of Business Administration from the International University of Japan and is a Fellow of the Financial Services Institute of Australasia. He was a three-term board member on a government enterprise with assets of over $350M. He was a founding director of a successful dot.com start-up in the early 2000s.

Andrew is an advocate of sport and fitness as a gateway to good health.  He is passionate about the role of genomics in identifying both the cause of disease and personalized solutions.

Sessions

Linkin Twitter Website

Bio

Phillip D’Costa is an experienced Partner specialising in commercial, fraud, IT and financial services dispute resolution, arbitration and ADR. Phillip has been ranked as a leading individual for UK and India dispute resolution in Chambers Global 2014 and foreign expert in Chambers Global 2015.

Key areas of practice:
• Commercial – Litigation & Arbitration, jurisdictional issues, partnership/LLP, contractual claims, shareholders, Technology, director’s duties and insolvency;
• Civil Fraud – Company investigations, restitution claims, misrepresentation, asset tracing, freezing & recovery, supply chain fraud, employee fraud;
• Financial Services & Regulatory – Securitisation, asset finance, leasing, share fraud, miss-selling, derivatives and structured products, money laundering, regulatory, compliance;• Has a particular interest in arbitration and transactional work involving India and has advised on a number of disputes and transactions involving India or Indian Companies, Families and Individuals.

Specialities:
Civil Fraud – Company investigations, Freezing Orders, Fraud investigation and Asset tracing.

Commercial – Litigation & International arbitration, jurisdictional issues, partnership and LLP advice and disputes, IT & IP disputes, contractual claims, shareholders disputes, Asset Finance & Leasing, Cross border transactions, Insolvency and Licensing.

Financial Services & Regulatory – miss-selling, money laundering, regulatory, compliance.

Sessions

Linkin e-mail Website

Bio

Manish is responsible for providing a strategic vision to NSDC in ensuring that the team moves cohesively in one direction towards achievement of the Prime Minister’s Skill India Mission. Manish also represents NSDC at domestic and international fora. He is also the official spokesperson for NSDC.

Sessions

Linkin Website

Bio

Raghav is a strategic, execution focused and entrepreneurial business leader, with proven track record in the consumer, internet and management consulting industries in India, south-east Asia and Europe. Have led three consumer internet businesses in India – Coursera, BlaBlaCar and Sucré Patisserie – and successfully created new spaces in the consumer domain. Have over 19 years of experience across Coursera, BlaBlaCar, Sucré Patisserie, Booz & Co and Technopak Advisors.

Sessions

Website

Bio

Sessions

Linkin Twitter e-mail Website

Bio

Francisco Marmolejo is the World Bank’s Lead Tertiary Education Specialist and Coordinator of its Network of Higher Education Specialists. He serves as the coordinator of the internal thematic group on higher education, which helps facilitate the exchange of ideas on higher education initiatives across the globe.

Previously, he served as founding Executive Director of the Consortium for North American Higher Education Collaboration (CONAHEC), a network of more than 160 higher education institutions primarily from Canada, the U.S. and Mexico, based at the University of Arizona (UA), where he also worked as Assistant Vice President.

At UA, he was Affiliated Researcher at the Center for the Study of Higher Education and Affiliate Faculty at the Center for Latin American Studies.

Sessions

Linkin e-mail Website

Bio

Anand Sudarshan is the Founder & Director of Sylvant Advisors Private Limited. Anand is also an independent director at NIIT. Till June 2012, he was Vice-Chairman & Managing Director of MaGE, where he has had a distinguished career since May 2006.

He currently advises companies & entities in the education sector, and is also a fund advisor with TVS Capital Funds. He is active in supporting Government of India in policy formulation, and is a member of select Committees & Task Forces of the Planning Commission of India as well as the Ministry of Human Resource Development.

Sessions

Linkin e-mail Website

Bio

Nathan Andrews believes in Working to deliver on the brand promise to all stakeholders while ensuring customer delight as well as the financial success of every business within the city. To make Lavasa India’s first hill city the preferred destination for residents, students and tourists. A city of learning, art and culture with a quality of life unparalleled in the country.

Sessions

Linkin e-mail Website

Bio

Professor Mammo Muchie holds a DPhil in Science, Technology, and Innovation for Development (STI&D) from the University of Sussex. UK. He is currently a DST/NRF rated Research Professor at the Faculty of Management Sciences, Tshwane University of Technology, South Africa. He is a fellow of the South African Academy of Sciences and the African Academy of Sciences. He is also currently adjunct Professor at the Adama Science, Technology University, Arsi University, Addis Ababa University and University of Gondar, Ethiopia. He has been senior research associate at the SPMTDC programme and also has become Senior Research Associate at the TMD Centre of Oxford University.

He is collaborating with researchers (DILIC) on the potential research areas of Africa-China industrial high-technology sectors. He has been invited as Associate Faculty professor at Sussex University, UK for the next three years; at the University of Economics in Prague as visiting professor, Jawarahal Nehru University India, Tonji and Shanghai University, China; Honorary Professor Jiaxing University, China, Assistant Professor Amsterdam University, Visiting Professor Carleton College, USA; Principal Lecturer, Middlesex University, Professor, Aalborg University; Part–time Lecturer, Cambridge University; Honorary Professor UNISA. Professor Mammo held various positions globally, including the Director of the Research Programme on Civil Society and African Integration at the then University of Kwa Zulu-Natal; board member at the North Western University, Chengdu, China.

He is currently the chairman of the advisory board of African Talent hub of the Community Interest Company (registration no.10461990) to raise funds for making Africa the talent, innovation, entrepreneurship, creativity and knowledge hub of the world. He has been appointed as special distinguished advisor to the Africa Union’s Student Council and a mentor for the African Entrepreneurship award. He has initiated the African Unity for Renaissance and Knowledge Exchange series of conferences since the last six years. He is a founding scientific advisor to ´the African Solar network, founding chairman of the Network of Ethiopian scholars. He has lead the SIDA, Sweden funded research on engineering design and on transformative innovation for African integrated development and educate on public media to speed up the creation of innovative and renascent Africa. He is also a co-founding member of the Nano Technology Institute in TUT leading the innovation side of the research.

Sessions

Linkin e-mail Website

Bio

Sessions

e-mail Website

Bio

Souvik Bhattacharyya graduated from Jadavpur University, Kolkata with a Bachelor’s degree (1981), MS (1985) from University of Cincinnati, USA and PhD from Texas A&M University (1991), USA – all in Mechanical Engineering specializing in thermal sciences. After a post-doctoral research stint at TexasA&M, he joined the faculty of IIT Kharagpur in 1991 where he was Dean (Students’ Affairs) during 2009-2012 and has been a Professor of Mechanical Engineering since 2003, Professor (HAG) since 2009. He also held faculty position at University of Canterbury, Christchurch, New Zealand during 1998-2000. He served as the Vice-Chancellor of Jadavpur University, Kolkata during August 2012–October 2013 and as Deputy Director of IIT Kharagpur during 2013-2016. Currently he is the Vice-Chancellor of BITS Pilani. Prof Bhattacharyya is a Member of the Research Council of CSIR-CGCRI, the General Council & Executive Board of ISM, Dhanbad and the Civil & Mechanical Engineering Project Advisory Committee (PAC) of SERB, DST.

 Dr Bhattacharyya has been on the Editorial Boards of International Journal of Power and Energy Systems and Journal of Nano Energy and Power Research. He is an Associate Editor of the international journal Alternative Energy and was on the Editorial Board of Energy Conversion and Management during 2007-2013. He was a member of the Committee on Fast track scheme for young scientists, DST during 2007 –2012. His research interests include heat transfer enhancement, thermodynamic optimization, energy engineering, natural refrigerant based transcritical heating-cooling systems, and natural circulation loops. A recipient of ASHRAE Best Paper Award, Dr Bhattacharyya has published about 220 research articles in indexed international journals and conference proceedings and is a co-author of the celebrated Heat Transfer text with J P Holman. 

He is a Fellow of the Indian National Academy of Engineering (INAE), National Academy of Science, India (NASI) and WB Academy of Science & Technology.

He is known as an adored teacher among the students of IIT Kharagpur and was the first recipient of the Outstanding Teacher Award of Indian National Academy of Engineering in its inaugural year in 2013.

Sessions

Linkin e-mail Website

Bio

Kishore Balaji has been working across multiple verticals, in many roles helping organisations build their strategies & businesses.

The spaces he has been engaged in so far ranged between Education, Training, Employability, Rural Dev, ICT for SMBs/ SMEs, Entrepreneurship & Innovation, Nation Building projects among others, acorss South Asia and APAC.

Sessions

Linkin e-mail Website

Bio

Dr. Chandra Bhushan Sharma, the present Chairman of the National Institute of Open Schooling (NIOS), is Professor of Education at the School of Education, Indira Gandhi National Open University, New Delhi.

He has taught for three decades and sat on many national committees and commissions constituted to advise governments and institutions. His expertise is in policy making from school to higher education especially distance mode education. He was one of the three member committee constituted by the Government of India to draft the Distance Education Council of India Bill. He has also been on the committee to suggest revamping of teacher education in India.

Sessions

Linkin e-mail Website

Bio

Pranjal lead venture capital investments, champion portfolio management in investee companies, and drive strategic projects for Bertelsmann Group companies in India. He has been part of A.T. Kearney India unit leadership, driving business development & project delivery in Communication, Media & Technology practice. Pranjal has expertise in shaping growth strategy and its operationalization, and in driving large-scale operational excellence programs for CXOs primarily in telecoms, retail, consumer goods and auto sector.

Sessions

Linkin Website

Bio

Sessions

Linkin Twitter e-mail Website

Bio

Dr. Ganesh has set up 5F World (www.5FWorld.com) as a meta start-up which scans the start-up eco-system and makes investments in select start-ups that transform employee and customer journeys. He is Executive Chairman of 5F World and also Chairman of two incubated firms, Global Talent Track and Skills Alpha.

Dr. Ganesh is a Senior Advisor for Digital Transformation with McKinsey & Co and the Pune Smart City Initiative and is currently leading the development of a Start-Up Hub in the city of Pune which will provide research to city investors and established firms and also support the mentoring and corporate linkages of start-ups anywhere which need to establish linkages with industry leaders in the Manufacturing, Financial Services, Information Technology and Business Process Management sectors of India. He is also advising start-ups in the USA Singapore and India which are focused on Digital Financial Services and Retail Commerce.

Sessions

Linkin Twitter e-mail Website

Bio

Poonam Heryani is the Head of Academics, ASPAM Indian International School, Sharjah. She is a much sought after speaker and trainer, she has led and conducted numerous workshops for school educators in India and the Middle East.

Having completed her MSED Research in Teacher Leadership from Richard Riley College of Education, Walden University, USA, currently Poonam’s area of interest is “How leadership practices in a school can impact the learning and achievement of students”.

Poonam provides Instructional leadership and teacher training, supports curriculum design that addresses what students must know factually, understand conceptually and be able to do in skills and processes, she addresses critical issues of improving instruction that develops conceptual thinking along with critical, creative and reflective thinking.

Having spent twenty eight years as an educator, Principal and school administrator, Poonam Heryani has become widely recognised as an ambassador for progressive education with a focus on designing and delivering curriculum, practices pertaining to curriculum reform, instructional strategies that encourage critical thinking and strategic planning.

Sessions

Bio

Professor Sir Malcolm Grant , CBE, FAcSS  is the Chairman of NHS England, formerly known as the NHS Commissioning Board. He is also a barrister and academic lawyer.

Grant was appointed as chair of the newly formed NHS Commissioning Board in 2011 by the Secretary of State for Health, Andrew Lansley. He was previously the ninth President and Provost of University College London – the head as well as principal academic and administrative officer of the university – for over a decade from 2003 until 2013. He is the current Chancellor of the University of York.

In August 2003, Grant left the University of Cambridge to become Provost and President of University College London.

In 2004, Grant launched ‘The Campaign for UCL’. The campaign was designed to generate 300 million pounds of extra funding for the university, to expand facilities and provide for new research initiatives. The appeal will also fund an ear institute, a spinal repair unit and an institute for women’s health. Fifty million pounds of the targeted funds will provide support for students, in the form of bursaries, scholarships, and post-doctoral fellowships. It was the biggest ever fundraising target set by a university in the United Kingdom, until Cambridge set a £1 billion target for its 800-year anniversary followed by the highest ever £3 billion target set by University of Oxford through the Oxford thinking campaign.

Grant said of the ‘Campaign’:

“I have heard it suggested that the concept of philanthropy is somehow alien to the national psyche, and that asking for money is not the British thing to do. This is, frankly, nonsense. Most of our leading universities owe their origins to philanthropy. Without the generosity of our founding fathers, UCL would never have seen the light of day back in 1826. This campaign will enable UCL, a real British success story, to enjoy the kind of resources to enable us to compete with the world’s very best academic institutions”

— Interview with BBC News, 2004

In 2005, on an invitation from The Cheese Grater, he agreed to shave off his moustache if UCL students raised £1500 for Comic Relief, on Red Nose Day. Unfortunately for his moustache — of 33 years — students and staff duly donated over £2,000. However, it has since regrown.

In 2006, he spoke out against the Israel university boycotts by the Association of University Lecturers (now the Universities Colleges Union). In 2006, Grant also controversially stated that European students had better English skills than many British students.

In 2007, Grant said the achievement and academic gap between male and female students was widening. Since 1998, 313,259 more women than men have made university applications. Malcolm Grant said, “the trend indicated a big fall in the number of university-educated men”.

In January 2007, he argued that the entire nationwide university approach to funding needed a different approach. In regard to UCL’s need for additional funding, he stated the reasons in an interview with the BBC:

“”To provide world-class research – through discovery, invention and creativity – and to convey the excitement of it to able young minds.”

— Interview with BBC News, 2007

In June 2007, in response to legal threats from Alan Lakin, husband of a purveyor of herbal remedies, Grant required Professor David Colquhoun to remove his website, “Improbable Science” from university computers. An outcry from the scientific community ensued, and Grant reconsidered, inviting Dr. Colquhoun to bring the site back to UCL once it had been edited for libel.

In December 2011, Grant became the first UCL Provost to be challenged by ‘a vote of No Confidence’ by UCL Union, the representative body of UCL students, following his appointment as chair of the NHS Commissioning Board. However this was deemed unconstitutional.^{[citation needed]} As a result, the matter was passed to a referendum in which the students of UCL voted in confidence of Grant by 1699 votes to 1185, with 391 abstentions.

Sessions

Linkin Twitter e-mail Website

Bio

Andreas Schleicher is Director for Education and Skills, and Special Advisor on Education Policy to the Secretary-General at the Organisation for Economic Co-operation and Development (OECD) in Paris.

As a key member of the OECD Senior Management team, Mr. Schleicher supports the Secretary-General’s strategy to produce analysis and policy advice that advances economic growth and social progress. He promotes the work of the Directorate for Education and Skills on a global stage and fosters co-operation both within and outside the OECD. In addition to policy and country reviews, the work of the Directorate includes the Programme for International Student Assessment (PISA), the OECD Survey of Adult Skills (PIAAC), the OECD Teaching and Learning International Survey (TALIS), and the development and analysis of benchmarks on the performance of education systems (INES).

Before joining the OECD, Mr. Schleicher was Director for Analysis at the International Association for Educational Achievement (IEA). He studied Physics in Germany and received a degree in Mathematics and Statistics in Australia. He is the recipient of numerous honours and awards, including the “Theodor Heuss” prize, awarded in the name of the first president of the Federal Republic of Germany for “exemplary democratic engagement”. He holds an honorary Professorship at the University of Heidelberg.

Sessions

Linkin e-mail Website

Bio

Justin van Fleet is also the Chief of Staff to the United Nations Special Envoy for Global Education, Former UK Prime Minister Gordon Brown. He serves on the Advisory Board of the Global Business Coalition for Education and works with the UK children’s charity, Theirworld, founded by Sarah Brown.

He was previously a fellow at the Brookings Institution’s Center for Universal Education in Washington, D.C. where his research focused on corporate social investments and philanthropy for global education. He graduated with a PhD from the University of Maryland in international education policy and holds a Master’s degree from Harvard University in the same field.

Sessions

Linkin Twitter e-mail Website

Bio

Throughout her career, Dr Mary Stiasny has worked tirelessly to both deliver and promote quality accessible education across the world.

Prior to becoming Pro Vice-Chancellor (International), Dr Stiasny provided strategic direction and leadership at the Institute of Education, in her capacity as Pro-Director with responsibility for Learning, Teaching and International.

Working life for Dr Stiasny began as a secondary school teacher in West London. She then joined Goldsmiths College, where she was involved in initial teacher education, becoming Director of PGCE and Deputy Head of the Department of Educational Studies. This was followed by a move to Oxford Brookes University, where she was appointed Deputy Head of the School of Education. She then returned to London, to become Head of the School of Education and Training at the University of Greenwich. Following this, she spent four years at the British Council as Director of Education and Training before joining the Institute of Education.

Dr Stiasny’s practical and strategic experience in education spans across a wide range of roles, including providing consultancy for a number of educational projects that have attracted external funding, and as an external examiner.

Sessions

Linkin Website

Bio

Marius Westhoff has more than 6 years experience across Corporate, Venture Capital & StartUp in Education & Digital Media across Europe, US and India. In charge of P&L for Verticals / Member of Founding Team to grow the venture and build careers of tomorrow.

Sessions

Linkin Website

Bio

Dr. Stephen Minger research has been at the forefront of human stem cell research. His group was the first to deposit a human ES cell line into the UK Stem Cell Bank and first to pursue Somatic Cell Nuclear Transfer (SCNT) to generate “hybrid human embryos” for research. Besides research, Stephen has been actively involved with the UK government helping legislate the first Human Embryo Bill in 2009 and being the Stem Cell Expert and Member of the UK Gene Therapy Advisory Committee (GTAC) at the Department of Health from 2006-2012 helping also the Chinese government with Stem Cell legislature.

In 2009 he was appointed first the Global Director for Research and Development for Cell Therapies at GE Healthcare. In 2013 he was appointed Chief Scientist for Cellular Sciences to lead their research for technology development within cellular therapies and diagnostics. He is a member of the Board of Directors of the Canadian Centre for the Commercialisation of Regenerative Medicine (CCRM) and Scientific Advisor for BioLamina. He also serves as the Director of SLM Blue Skies Innovations Ltd, providing expert analysis in emerging healthcare technologies for the life sciences investment community.

Sessions

Website

Bio

Patricia Hewitt is the Chair of the UK India Business Council (UKIBC), the premier business-to-business network that works with the British Government to promote bilateral trade between the UK and India.

Patricia Hewitt had a long and distinguished career in politics and government, including as the longest-serving Secretary of State for Trade and Industry in the last fifty years. In that role, she made India her top international priority, believing – as she said in 2002 – that India was rapidly becoming ‘the world’s most exciting knowledge-driven economy’. She also served in Tony Blair’s government as Cabinet Minister for Women (2001 – 2005) and Secretary of State for Health (2005 – 2007). Between 1997 and 2010, Patricia was Labour MP for Leicester West and continues to have close ties with the city and its large British Asian community.

Patricia is a non-executive director of EuroTunnel, a member of the International Advisory Board of Sutherland Global Services and a senior adviser to FTI Consulting. She was for many years Senior Independent Director of BT, where she chaired the remuneration and pensions committees, and a member of the UK government’s Asia Task Force. She is also a member of the UK India Round Table.

For the last six years, Patricia has been an active supporter of Katha, a ‘profit for all’ social enterprise that is transforming the lives of children and their families in Delhi’s slums. She chairs the donor consortium established by the British Asian Trust – one of the Prince of Wales’s Trusts – to support Katha’s work.

In October 2014, Patricia was selected by the British Government to receive the first Dadabhai Naoroji award to recognise her contribution to economic ties between the UK and India.

Born in Australia, Patricia took her undergraduate degree at Cambridge University, and has been awarded an MA by both Cambridge and Oxford. She is an Honorary Associate of Newnham College, Cambridge, an Honorary Doctor of De Montfort University and an Honorary Fellow of the London Business School.

Patricia’s husband, William Birtles, has recently retired from a long career as a barrister and senior judge at the Mayor’s and City of London Court. They have a daughter and a son, both in their 20’s. In her spare time, Patricia enjoys reading, music, theatre and gardening. Although her efforts to learn Hindi have not been very successful, she wowed the Vibrant Gujarat summit in January 2013 with her speech in Gujarati!

Sessions

Linkin e-mail Website

Bio

Pramath Raj Sinha is a Senior Advisor of the Albright Stonebridge Group, India and the Founder and Managing Director of 9.9 Mediaworx Private Limited. Prior to founding 9.9 Media, he was a Partner at Mckinsey and led the ABP Group, one of India’s leading and most diversified media conglomerates.

Pramath helped set up and served as the Founding Dean of the Indian School of Business (ISB). He continues to be a member of its Board of Governors.

Pramath is a Director on the Boards of PRADAN, India’s leading development institution focused on improving livelihoods in the country’s poorest district and of the Central Square Foundation, a philanthropic fund focused on improving the educational outcomes for low-income children in India. He holds a Bachelors degree from IIT Kanpur and an MSE and PhD from University of Pennsylvania.

Sessions

Website

Bio

Mr. Francis Joseph has more than 20 years of Management experience in School Education; in areas that include School Operations, Human Resource, Technology, Organizational Development and Strategy Planning.

He has extensively worked in establishing and managing schools for one of India’s Largest Singly owned/managed & non-franchised Educational group as its COO in India & Middle East (till year 2011), from where he started as a Teacher in year 1993. He was also instrumental in developing many technological initiatives and revolutionary practices in Schools, both in India and abroad. Francis is also a recipient of the “Limca Book of Record” (Edition 2013) for managing the fastest School admission process (10 days) in the country; which was also appreciated by the HRD Minister of State, Government of India and then Chief Minister of Gujarat, Shri. Narendra Modi.

Francis Joseph has established and operated several prestigious schools in India and Middle East; pursuing curricula of Indian and International Boards. Francis was also selected as an emerging edupreneur in India (year 2013) for an incubator programme conducted by the Pearson Affordable Learning Fund (U.K.) for his efforts in affordable and low-cost education in smaller towns and villages. Francis is also associated with the Archdiocesan Board of Education (Mumbai) and CfBT India in their school development projects. Francis is the Vice-President of Early Childhood Association (India), a private NGO in early childhood care and education with members from all across the country. His core strengths are high-level networking, communication skills, people management, technology enabler, service oriented, grass-root level experience in establishing schools and developing strategy related to perception building, marketing and scalability.

Sessions

Linkin Website

Bio

Harriet  Fear joined One Nucleus (formerly ERBI) as CEO in February 2009. She previously worked as a Diplomat with the British Foreign Office for 21 years serving in over 17 countries around the globe. Half her career was spent in the commercial field, latterly heading UK Trade & Investments national life sciences trade team for over 5 years.

She was attracted to the role at One Nucleus because she wanted to spend time helping companies maximise their competitiveness and to lead a team which already had an excellent reputation. Since her arrival at One Nucleus, the company has redefined its membership (now life science and healthcare, not only biotech), formed strong and strategic relations with like minded US counterparts for the benefit of members and merged ERBI with London Biotechnology Network to enhance the offer to members and create a stronger critical mass on the international stage.

One Nucleus is the largest membership organisation in Europe. A not-for-profit private company, it has over 450 members including pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial service providers.

The One Nucleus mission is to maximise the global competitiveness of its members. For their science and technology-based members, this means being global leaders in the research, development and commercialisation of healthcare innovations that radically improve the quality of people’s lives around the world. For their business and professional services members, it means delivering exceptional services that significantly enhance the business performance of their clients.

Harriet Fear has accepted the Prime Ministers invitation to continue in her UK Business Ambassador role for a further two years to 2017. She continues to be Chief Executive of One Nucleus – her first priority and passion. By accepting this invitation, Harriet has agreed to undertake, in the margins of her personal or business travel, a programme of activities developed by and with the Government until July 2017. This could include for example, hosting a reception in a country she is travelling to in order to highlight UK expertise in the life science and healthcare sector, briefing UK Ministers and HM Ambassadors on key business priorities and interests as they might arise; meeting overseas Ministers and inward missions; and providing insights into how UK Trade & Investment can better deliver for business.

Sessions

Linkin Twitter e-mail Website

Bio

Lord Karan Bilimoria CBE, DL is the founder of Cobra Beer, Chairman of the Cobra Beer Partnership Limited and of Molson Coors Cobra India, both joint ventures with the global brewing company, Molson Coors.

He is the Founding Chairman of the UK India Business Council, a Deputy Lieutenant of Greater London, a former Chancellor of Thames Valley University (now the University of West London); he was the youngest University Chancellor in the UK when appointed.

In 2014, he was appointed as the 7th Chancellor of the University of Birmingham and was the first Indian born Chancellor of a Russell Group University in Great Britain. Karan is Senior Non-Executive Director of the Booker Group PLC, the FTSE 250 Company of Booker Prize fame; he is one of the first two visiting entrepreneurs at the University of Cambridge; he is a founding member of the Prime Minister of India’s Global Advisory Council.

In 2006, Karan Bilimoria was appointed the Lord Bilimoria of Chelsea, making him the first ever Zoroastrian Parsi to sit in the House of Lords. In 2008 he was awarded the Pravasi Bhartiya Samman by the President of India. He is an honorary fellow of Sidney Sussex College Cambridge and Chairman of the Advisory Board of the Judge Business School, Cambridge University.

He qualified as a Chartered Accountant with Ernst & Young and graduated in law from the University of Cambridge. He is also an alumnus of the Cranfield School of Management, the London Business School and the Harvard Business School. In 2015, Karan Bilimoria was appointed President of the UK Council for International Student Affairs (UKCISA).

Sessions

Linkin Twitter e-mail Website

Bio

An insightful legal, finance and diversity expert, Miranda Brawn has made a successful portfolio career for herself. Brawn has a robust track record managing teams and clients for the world’s largest banks, such as Goldman Sachs, JP Morgan Chase and Deutsche Bank. She has previously worked in senior middle office management roles and the front office as a sales trader. Today, Miranda manages the legal risk in Europe for derivatives, regulations and securities financing within an investment bank.Brawn has many strings to her bow and is well known for her passion in philanthropic and diversity issues. Moderator and public speaker for diversity, legal and finance events internationally. She advises ‘Game Changer’ firms and is their Ambassador in the media. Examples include where she is the Patron for the “Black British Academics” and the Vice-Chair for the “Black Cultural Archives”.She holds Post Graduate Diplomas in Management and Law, Master in Business Administration (MBA) degree in Strategic Management and Finance, passed the Bar of England & Wales (Lincoln’s Inn), studied News Journalism at The London School of Journalism & Political Philosophy at Cambridge University.

Sessions

Linkin Website

Bio

Vipul Jain is a serial entrepreneur who specialises in spotting business opportunities while they are still in nuance stage. An MBA from Rochester Institute of Technology, Rochester, New York, class of 1999, I started my career by establishing a fabrics import business as an extension of the family business of Garment exports in 1999.

In 2002 I established an animation studio by the name of Mirage Animation which produces television quality animations for clients such as Warner Brothers, Disney, Channel 5 etc.

In 2003, I spotted an opportunity in Medical Tourism sector while the world was still to wake up to the phenomenon. Vipul helped founding a company called PlanetHospital and built it to be the worlds largest medical tourism company. I exited the company in 2011 to establish my own Medical Tourism business by the name of Mirage Medserv focusing on the third world countries, Russia, Africa and Mid East. Mirage is today one of the largest facilitators of patients of almost all major hospitals in the country.

In 2013, I established Advancells, which is a research based company focusing on providing cutting edge Stem Cell Therapies for patients with life threatening diseases also catering to lifestyle diseases and anti aging technology. Advancells is slowly rising to be a leader in a very small space of modern medicine and is in process of filing patents for treatment of multiple diseases.

Sessions

Linkin Website

Bio

Dr. Villoo Patell is an Academic Entrepreneur who founded Avesthagen in 1998. Avesthagen is globally recognized as a leading systems biology company with a unique model focused on the convergence of food, pharma and population genetics. A convergence that leads to continuous and path-breaking innovations in predictive, preventive, personalized healthcare. Owing to her pioneering work in the field of molecular biology, Dr. Villoo Patell has long-standing professional relationships with individuals, institutions and corporates working in the domain of biotechnology across the world. She is a key member of the Task Force and Vision Group for Biotechnology, instituted by the State Government of Karnataka and founding member of the Association of Biotechnology Led Enterprises (ABLE). Dr. Villoo Patell was Awarded the ‘Officer of the National Order of Merit’ by the President of the French Republic in April 2008.

Dr. Villoo Patell has worked with Dr. Richard Jefferson to initiate the development of pCAMBIA vectors for transformation of crops with both agrobacterium and biolistic methodologies. The pCAMBIA range of vectors, today, are used worldwide by agricultural researchers and the project was funded by the Rockefeller Foundation.
Dr. Villoo Patell has worked with Dr. Richard Jefferson in creating vectors for transformation of rice by both agrobacterium and biolistic technologies. (This was the first start to the creation of pCAMBIA vectors that went on to become used by agricultural researchers in the world.).
Funded by the Rockefeller Foundation.

Sessions

Twitter Website

Bio

Navtej Sarna is a diplomat and author. He graduated from Delhi University in 1980 with degrees in Law and Commerce and joined the Indian Foreign Service the same year. He has served in various diplomatic capacities in Moscow, Poland, Bhutan, Geneva, Iran and Washington . His recent appointments were as the Foreign Office Spokesman and India’s Ambassador to Israel. Presently he is serving as a Secretary to Government of India in the Ministry of External Affairs.

Navtej Sarna is the author of the novels ‘We Weren’t Lovers Like That’ (Penguin India, 2003) and ‘The Exile’ (Penguin India, 2008) as well as the short story collection ‘Winter Evenings’ (Rainlight Rupa, 2012). His non-fiction works are ‘The Book of Nanak’ (Penguin India, 2003), ‘Folktales of Poland’ (Sterling 1991) and ‘Indians at Herod’s Gate’ (Rainlight Rupa, 2014). He has translated Guru Gobind Singh’s ‘Zafarnama’ (Penguin India 2011) from Persian to English as well as the Punjabi partition stories of Mohinder Singh Sarna in ‘Savage Harvest’ (Rupa, 2013). He has been contributing regularly to journals and newspapers in India and abroad including The Times Literary Supplement, London Magazine, The Hindu, India Today, Outlook and so on. His literary column Second Thoughts that appeared in The Hindu for seven years is being brought out as a collection by Harper Collins.

Sessions

Linkin Website

Bio

Priya Krishnan is an MBA from London Business School and has worked in Various leadership positions with Anderson Consulting and Mphasis across Singapore, New York, London and India.Founder CEO of Founding Years Learning Solutions Pvt Ltd., India’s leading childrcare and schooling service provider with over 45 owned operated centres across Bangalore, Hyderabad, Mumbai, NCR and Chennai

She started the company with the intent of enabling women to get back to work post childbirth. With this in mind we provide high quality child care services onsite (for corporate like Unilever, ITC, L’Oreal, Johnson and Johnson, Airtel among others). We also work with corporates in near workplace models and help them with creating solutions for the employees through subsidies and underwriting (like in the case of Accenture, IBM, Flipkart etc.)

With 5 years of operations behind us and 2000+ children under our care what differentiates us is our transparency, flat organizational structure and empowered center staff.

She has worked across the world prior to moving to India to start up Klay and that experience has stood me in good stead.

Sessions

e-mail Website

Bio

Phil Jackson previously held a range of senior positions within the Canadian healthcare system, as Director of Strategic Support and chief adviser to the Medical Officer of Health for the City of Toronto Health Department, the largest public health department in North America with 15 offices and 1,800 staff. Prior to this Phil led the development and establishment of the Ontario Agency for Health Protection and Promotion, with 14 laboratories and 600 plus staff, serving as the founding Vice President of Strategy and Planning. Phil served as part of the control team for the SARS outbreak in 2003 and the H1N1 outbreak of 2009.

Phil Jackson,As Head of Research to the Expert Panel on SARS, Phil led the drafting of a major two volume expert report into Infectious Disease Control and Emergency Response (the Walker report). Phil had served as the Canadian representative to the OECD working group on New Genetic Technologies and serving as Ontario Director for Health Information and Sciences led the drafting of an internationally acclaimed report on Genetic Testing. Phil has led a wide range of major health system initiatives in his career including leading the complete red-design of Stroke prevention, treatment and rehabilitation services for a population of over 11m people, the implementation of Hospital Report Cards across 134 hospitals, the establishment of 14 Regional Infection Control Networks and multiple other initiatives. Phil is the recipient of several Canadian awards for health reform, most recently the Amethyst Award and Ace Award.

Sessions

Linkin e-mail Website

Bio

Dr. Anil Wali is currently the MD at Foundation for Innovation and Technology Transfer (FITT) – an autonomous industry interface organization of IIT Delhi. He is managing technologies and driving innovations and enterprise at the academia besides looking at issues of concern to SMEs. He has worked in chemical industry for 19 years before taking up the present position. Besides several publications, patents and reports to his credit, he has a strategic customer and quality orientation, and brings a practical perspective to solving technical problems. He is also called upon to deliberate and participate in the area of clean technology and sustainability. His multifaceted experience towards technology innovation and management, industry partnership, project issues, entrepreneurship, IPR, education, training, etc is sought for advice / association with several committees and programmes. He is an IIT Delhi Doctorate.

Dr. Anil Wali at Foundation for Innovation and Technology Transfer (FITT) believes that FIIT is an industrial interface organization, established at the Indian Institute of Technology Delhi (IIT Delhi) as a Registered Society on 9th July 1992. Dr NC Nigam was the founding Chairman of FITT, and Dr AK Sengupta was the first full-time Managing Director. IIT Delhi’s Review Committee Report -1986, recommended the setting up of an industrial foundation to enhance the programmes of interaction and collaboration between IIT and industry. To implement this recommendation the Institute took up this initiative, with a seed grant received from government at that time, which, led to the setting up of FITT.

FITT aims to be an effective Interface with the Industry to foster, promote and sustain commercialization of Science and Technology in the Institute for mutual benefits. For over twenty years now, FITT has been an interface between the Institute and the industry and has been devising innovative ways to create partnerships and linkages with business and community to enable knowledge transfer for common good. The team at FITT and academicians from IIT Delhi has been largely responsible for the successful outreach efforts including extensive S&T collaborations.

Sessions

Linkin Twitter e-mail Website

Bio

Currently Julie Stone has responsibility for the leadership of Online Distance Learning at the University of Derby,and leads a team of staff dedicated to this business activity.

She was also involved, as Business Manager at University of Derby, in establishing the largest franchise within the HE sector and has led the Online Distance Learning project through to substantial and progressive growth.

As Head of Quality Assurance at Gloucestershire University, she helped the College of Higher Education achieve University status and gain degree of awarding powers.

Sessions

Linkin Website

Bio

Dr Michel Baijot is Head of Cipla Global Vaccines. He is a life science executive bringing over 25 years of experience in building vaccine businesses with significant contribution in strategy, licensing, M&A, technology transfer and finance. His positions with both biotechs and big pharmas (GSK Vaccines, JnJ Crucell) and his concrete achievements in the vaccine marketplace reflect an in-depth knowledge of the vaccine environment in developed and developing countries. In his role of Head of Cipla Global Vaccines, he is leading the Cipla – Serum Institute of India partnership. He has been Chairman of the Belgian Biotech Association.

General/Business Unit Management, Healthcare, Big Pharma and Biotech,In Both Developing and DevelopedCountries,25 Years Worldwide Experience/Network in Vaccines, Mabs and Diagnostics

Sessions

Linkin Website

Bio

Yvonne Naughton was previously Head of Business Development and New Product Planning in the UK and Ireland for over three years, and before that held several positions at Sanofi in market access opportunities in Paria and Ireland for cardio thrombosis and arrhythmias. Before Sanofi, she was clinical safety officer at Novartis, and worked in drug safety at Quintiles. She has a PhD in Pharmacology from University College Dublin.

Yvonne Naughton was leading the UK and Irish side of our Global External Science & Partnering organisation. Our remit is to collaborate externally with academic institutions, spin-outs, start-ups, biotechs and non for profit organisations, in order to build Sanofi R&D’s early stage pipeline and accelerate the translation of innovation discovered in the UK and Ireland.

A strategic priority for Sanofi is to sustain innovation in R&D. We will increase our annual global R&D investments to €6bn by 2020, with an increased capacity for external innovation.
Our research interests and investment focus fall into 2 categories. 1: Where we would like to sustain our leadership- Diabetes, Cardiovascular Disease and Genetic Rare Diseases. 2: Where we would like to build a competitive position- Immunology, Oncology and Multiple Sclerosis. We will also invest opportunistically in Neurodegeneration/Pain, Infectious Disease and Ophthalmology.

Sessions

Linkin Website

Bio

Yichen Shi gained his doctorate in neuroscience and stem cell biology from the University of Cambridge. During his research he identified the need for a high-quality supplier of human cells; both iPSC-derived and primary, complete with media, supplements and all the critical ingredients for successful research with human cells. His entrepreneurial spirit combined with his passion for cell-biology led to the creation of Axol where innovation, quality and customer service are the key drivers.

Axol produces highly validated, human cells and critical reagents such as media and growth supplements. We have a passion for great science, delivering epic support and innovating future products to help our customers advance faster in their research.

Our expertise includes reprogramming cells to iPSCs and then differentiating to various cell types. We supply differentiated cells derived from healthy donors and patients of specific disease backgrounds. As a service, we also take cells provided by customers (primary or iPSC) and then do the programming (when necessary) and differentiation.

Sessions

Linkin Twitter Website

Bio

Venkateswarlu Nelabhotla comes with a very rich and global experience of successfully leading organizations in the Life sciences and Consumer Products businesses. He has held top management roles in the life sciences space in companies like Shantha Biotech (A Sanofi Company) and Aurobindo Pharma and he immensely contributed to their all-round growth. Shantha Biotech – a biosimilar and vaccine company, was eventually acquired by Sanofi for around $ 800 MN in 2010. He has been a part of significant revenue growth and significant value creation in Aurobindo Pharma in the global business segment of APIs and finished dosage form products in multiple therapy areas. He has held CEO roles in Emami and Cavinkare, CPG companies, growing them significantly with an all rounded approach. During his stint at Emami (a listed company) as CEO, the company’s market cap went up from $ 300 MN to $ 1.2 BN. The momentum thus created, has made Emami a $ 3.7 BN market cap company now. During early part of his career, he created some very successful brands in Cavinkare, a leading CPG company from India, and built the organization with a 10X revenue increase in 6 years’ time and that early momentum has made Cavinkare one of the established Consumer product companies in India. He comes with core strengths in Strategy, Innovation, Marketing, Organization building, Finance, M&A and Governance. He has been an integral part of many industrial forums in Life sciences and CPG business.

Sessions

Website

Bio

Stephen Shuttleworth joined Karus as CSO in 2008, and is the founding scientist of the company’s PI3K-p110β/δ and HDAC6 programs. Over the last 21 years, he has established a strong track record in R&D management, and in the design and development of molecular-targeted therapeutics for cancer, immune-inflammation and metabolic diseases. Prior to Karus, Stephen held senior positions in UK and North American biotech, notably at Celltech-Chiroscience (UK), BiochemPharma-Shire (Quebec), Tularik-Amgen (California), CRUK, and Piramed (UK) where he directed the PI3K-p110α and p110δ programs, designing and leading the preclinical development of GDC-0941 (Pictilisib), currently in Phase II cancer trials, under the auspices of Roche, who acquired Piramed in 2008 for $175M.

Stephen Shuttleworth has authored over 130 publications and patents, has been an invited speaker at over 40 major international conferences, and is a recognized opinion leader in the PI3K and HDAC arenas. He obtained his BSc and PhD in Chemistry from the University of Liverpool, and was made a Fellow of the Royal Society of Chemistry in 2007.

In 2014, he was appointed Professor and Honorary Chair at the University of Manchester (Faculty of Medical and Human Sciences) in recognition of his work on small molecule drugs to treat chronic human diseases.

Sessions

Linkin Website

Bio

Dr. S.D. Ravetkar is an Executive Director with Serum Institute of India Ltd. Apart from his Doctorate he holds degrees in Management and Finance. He has authored various research articles in national and international journals. He is also on advisory board of various national and international organizations and journals. He has more than 43 years techno-commercial experience in biotech industry in various areas like QC, production, projects planning & research. At present his major responsibility is manufacturing of Bacterial combination vaccines mainly Pentavalent and Hexavalent vaccine. He has extensively worked on microbial and bioengineering aspects of vaccinology and also has got expertise on technology transfer. He has widely traveled worldwide. He is listed amongst 15 influential figures in the Asian Vaccine Industry.

Dr S D Ravetkar, Executive Director, Serum Institute of India says that the company has put programme in place to achieve the ambitious plan to offer new vaccines

Serum Institute of India Ltd., is the worlds no. 1 producer of Diphtheria, Tetanus, Pertussis, HIB, BCG, Hepatitis B, Measles, Mumps, Rubella vaccines. It is estimated that about 60% of the children in the world receive at least one vaccine manufactured by Serum Institute of India Ltd.

Key focus in the coming year will be enhancing further capacities of above vaccines for which state of art plants are under various stages of completion. The growth has its own problems and challenges. Planned programme has been put in place for handling these issues.

Major thrust is also given on further strengthening quality systems by adding Process Analytical Technology (PAT) in various stages of manufacture of vaccines. More focus is given on incremental innovation than only on disruptive innovation. The technical team building by establishment of new training center is given major thrust.

Serum is also working with various Universities and Research Institutions in country and overseas, in Europe and U.S. to leverage advantage of mutual strengths in knowledge building. The development of critical knowledge mass is thus at center of various activities.

With robust pipeline of various newer vaccines in offing structured programme is carried to reduce time to market. Products on the horizon are many like Rota and Pnemococcus and HPV vaccines. This in itself is a gigantic task of putting new R & D incubators and going through entire process of germination of idea till commercialization.

Innovation is also being implemented in supplying various new vaccine administration systems and for effective measurement thereby validation of cold chain management.

These efforts will help make vaccines available at affordable cost to infant population in world. With acquisition of Bilthoven Biologicals in Netherlands Serum Institute of India Ltd., is looking for entry in Western regulated markets, In years to come as our vaccines are already manufactured in world class environment confirming to International FDA.

Sessions

Linkin Website

Bio

Sakate Khaitan is the senior partner at Khaitan Legal Associates. Sakate divides his time between London and Mumbai.

Sakate Khaitan heads the corporate M&A, funds, restructuring and insurance practice at Khaitan Legal Associates. Sakate advises clients on inward investments into India and on an array of India-focused cross border transactions. Having started his career in litigation, Sakate has over 11 years of litigation experience advising various clients in their disputes that included high profile joint venture disputes, tax disputes and disputes with regulators. Sakate also serves on the boards of several companies as a non-executive director, lending his legal and business acumen to businesses around the globe. Sakate assists clients with pragmatic and commercially sound advice on dealing with Indian rules and regulations. His clients include multinationals, private equity funds, financial institutions, fund managers, and HNIs.

In his experience that spans over two decades Sakate Khaitan demonstrates a deep commercial understanding of several industry sectors and significant transactional insights that offer immense value to the client.

Sakate Khaitan is the alumnus of London Business School (“LBS”) and is also the co-founder of the India Business Forum (“IBF”) at LBS. The IBF is a platform that was created to build awareness and facilitate discussions on and encourage cross border investments to/from India.

Sakate Khaitan is dual qualified and is a member of the Bar Council of India and is also admitted as a solicitor of the Supreme Court of England and Wales. However, he exclusively practices Indian law.

Sessions

Linkin Website

Bio

Dr Maryam Atakhorrami is an Industrial Partnership Manager with Translational Research Office in UCL. She works with key stakeholders of Faculty of Medical Sciences, to identify, create and manage strategic industrial partnerships for selected priorities of UCL in medical sciences. Maryam has a PhD in Biophysics from Vrije Universitiet Amsterdam. She has extensive experience of working in health care industry in various corporate Research and Innovation function, predominantly with a focus on new business development, strategic research alliances and open innovation management in private and public sector.

The Faculty of Life Sciences undertakes world-leading research and teaching, which combines the strengths of UCL’s basic biological and preclinical sciences. Our work attracts staff and students from around the world and together they create an outstanding and vibrant environment for both students and researchers. It is one of four Faculties within the UCL School of Life and Medical Sciences.

Research in Biosciences is carried out in Research Departments which bring together a critical mass of individuals with related interests. The Research Departments span the scale required to understand biological systems from molecules through to populations.

Sessions

Linkin Website

Bio

Rahul Garella is Senior Vice President, Head of International Pharmaceuticals at Endo Pharmaceuticals

– Leadership experience with full P&L responsibility for European subsidiaries.

– Top line and EBIDTA targets and overall P&L management and delivery.

– Leadership and strategy to bring differentiated generics and speciality products across Western Europe.

– Business strategy including licensing, building front ends, acquisitions and partnering

– Rich geographical experience in Europe, Asia Pacific and South America

– On the Editorial board of ‘Journal of Generic Medicines’ Past Recognitions/Awards:

– Led Glenmark, UK and achieved recognition for business performance by the London Stock Exchange group through their publication ‘1000 Companies to Inspire Britain’ (www.1000companies.com) in December’13

– Achieved recognition for Glenmark as amongst the fastest growing companies in the UK though a report by the CII (Confederation of Indian Industry) and Grant Thornton in its report ‘India meets Britain’ in March’14‘ Specialties: Business development for Generics (APIs and finished dosages) with companies in Europe, Latin America and Asia Pacific.

Recognition/Awards:

– Led Glenmark, UK and achieved recognition for business performance by the London Stock Exchange group through their publication ‘1000 Companies to Inspire Britain’ (www.1000companies.com) in December’13

– Achieved recognition for Glenmark as among the fastest growing companies in the UK by the CII-Grant Thornton in their report ‘India meets Britain’ in March’14‘

Sessions

Linkin Website

Bio

Naveraj Gill joined the department in 2002 to complete an EngD in collaboration with HEL Ltd. The project was based on the design and characterisation of an automated miniature bioreactor system for microbial culture. Following this Nav remained in the academic field as a postdoctoral researcher at UCL. She first worked on a large Technology Strategy Board (TSB) grant in collaboration with the Health Protection Agency (HPA) and Syntaxin.

Naveraj Gill research focused on the integration of microscale technology for the rapid development of bioprocesses and design for manufacture of biotherapeutic fusion proteins. She then worked as part of the IMRC in Bioprocessing investigating ultra scale-down microwell-based techniques for studying mammalian cell culture processes for the production of biopharmaceuticals with a view to scale-up to conventional and single-use bioreactor formats. This led to a position with GE Healthcare as a Single-Use Technologies Specialist, which evolved into a wider business development role for upstream technologies covering UK and Ireland. Key responsibilities included designing in single-use technologies, devising strategies for growing the upstream business, consulting on new product developments and managing new product launches.

Naveraj Gill has now returned to UCL as the Strategic Alliance Director to support the department in forging new links with companies and to foster existing relationships, creating a platform for knowledge transfer. She manages the MBI® industrial training programme which has trained over 1,300 individuals from 300 international companies and is the Business lead for the VISION Programme for Senior Executives.

Sessions

Linkin Website

Bio

Keith Foster, VP of Ipsen bought the biotech and its drug development platform Syntaxin for $37 million upfront with promises of about $170 million more, with most of the money pinned to the fate of a mid-stage therapy for a rare ailment. Dr Foster is a co-founder of Syntaxin, and joined Ipsen to build a botulinum toxin biology platform for new drug development covering a variety of fields. Back in 2010 Ipsen joined a consortium of investors to put $29 million into Syntaxin. The company held a 10% stake in Syntaxin at the time of the buyout.

Sessions

Linkin Website

Bio

Kay Brickmann is an experienced PhD business development and licensing professional with a significant track record of successful negotiations and completed deals. More than 17 years of post-doctoral experience in the pharmaceutical industry with scientific expertise in the field of cardiovascular R&D evidenced by author-/co-authorship of 15 research papers and 13 patents. Transactional experience with entities in Europe, USA, Japan and China, full understanding of the pharmaceutical drug development process from early discovery to marketing and a fluent German, English and Swedish speaker.

Recently, Kay Brickmann reported ethyl nicotinates as antagonists of the P2Y12 receptor, which is an important target in antiplatelet therapies. A potential liability of these compounds was their generally high in vivo clearance due to ethyl ester hydrolysis. Results: Shape and electrostatic similarity matching was used to select five-membered heterocycles to replace the ethyl ester functionality. The 5-methyl and 5-ethyl-oxazole bioisosteres retained the sub-micromolar potency levels of the parent ethyl esters. Many oxazoles showed a higher CYP450 dependent microsomal metabolism than the corresponding ethyl esters. Structure activity relationship investigations supported by ab initio calculations suggested that a correctly positioned alkyl substituent and a strong hydrogen bond acceptor were necessary structural motifs for binding. In rat pharmacokinetics, the low clearance was retained upon replacement of an ethyl ester with a 5-ethyl-oxazole. Conclusion: The use of shape and electrostatic similarity led to the successful replacement of a metabolically labile ethyl ester functionality with 5-alkyl-oxazole bioisosteres.

Sessions

Linkin Twitter e-mail Website

Bio

Denise is a NewLaw pioneer and has been spearheading operational, structural and cultural change within the legal services industry since starting Halebury in 2007. Her aim: to create an entirely original business model to service the needs of clients and lawyers at the senior end of the market. Denise has persuaded many clients, who would generally look to a panel of large firms for legal advice, to try a new service delivery method. The firm now has strategic partnerships with clients such at BT and Expedia, a growing roster of clients in the TMT and FS sectors and a team of 30 senior in-house lawyers. Denise is client lead on many of these accounts and heads up both service and product innovation to continuously improve and develop Halebury’s proposition.

Denise is a gamechanger in more ways than one. She has successfully and uniquely combined her legal and television career, launching and managing Halebury whilst presenting for Sky News and BBC One’s Escape to the Country. She continues with her media career as she strongly believes that experiences outside the legal industry can enhance your legal outlook and lead to innovation. She combines both careers with raising a young family.

Denise’s vision and determination to create an alternative in the traditional legal services market is borne out by Halebury’s success, evolving business model, recognition in the marketplace, and growing roster of high quality clients. She remains passionate about collaborating with clients to anticipate and meet their requirements. Her lead on customer service within the business has led to her being asked to speak on the subject to FTSE 100 clients.

Sessions

Linkin Website

Bio

Kartik Kumaramangalam has worked with multiple high tech startups in his career as an investor and early stage co-founder including Webex (acquired by Cisco) where he was an early founding employee. He has worked in private equity consulting at Boston Consulting Group in New York, and has been a hands on venture capital investor in several successful early stage technology companies in the US and India. Kartik’s undergraduate and master’s degrees are in Astrophysics undertaking research in solar neutrinos at Oxford University, before switching fields and completing his PhD at the London School of Economics as an Interdisciplinary Scholar for his applied mathematical research on scientific labor markets. He is currently also a Visiting Fellow at MIT.

Kartik Kumaramangalam is an active investor and advisor to start-ups and investment projects in Singapore, India and the US. He has previously worked at Boston Consulting Group in New York, been an early employee at WebEx (acquired by Cisco), advised the organization of His Holiness the Dalai Lama on economic policy and was a researcher on a Nobel Prize winning experiment in Astrophysics at Oxford University.

Kartik Kumaramangalam is also a Fellow at MIT and has taught and done research at MIT, London School of Economics and London Business School on the economics of intellectual property and tech driven economic growth. Kartik completed his PhD at the London School of Economics as an Interdisciplinary Scholar winning the Academy of Management Award for his research on scientific labor markets and the economics of ideas. He first trained as an an Astrophysicist specializing in solar neutrino physics as an undergraduate and graduate student at the University of Sussex and the University of Paris.

Kartik’s commitment to economic development comes from a strong background in public service in India with family members who have served as the Governor of Maharashtra, Chief Minister of Madras Presidency, Chief of the Indian Army, Cofounder of Air India (the national carrier) and Cabinet Ministers for Law, Education, Company Affairs, Power, Science, Technology, Coal and Mines.

.

Sessions

Linkin Website

Bio

Karin Conde-Knape is Vice President of Cardiovascular & Metabolic Scientific Innovation at Johnson & Johnson Innovation, London.

Previously, Karin was Global Head of Discovery in the CVM DTA at Roche where she was responsible for all the Early Research efforts as well as the Translational Biomarker and experimental medicine group. While at Roche, Karin was directly or indirectly responsible for identifying and managing numerous external collaborations with well renowned institutions worldwide. In addition, throughout her career at Roche, she had several roles, including laboratory head, project leader, head of pharmacology and co-department head in the CV and Metabolism Disease and Translational Area, both in the US and in Switzerland. She was responsible for setting and implementing the pharmacology strategy for the portfolio in the CVM group in areas such as Diabetes, Atherosclerosis, Dyslipidemia, Kidney, and CV disease.

Karin received her PhD in Nutritional Sciences from the University of Connecticut, and completed her post-doctoral fellowship at Columbia University.

Responsible for identifying, establishing and managing External Scientific opportunities from Early research to Clinical POC in the aread of Cardiovascular and Metabolism.

Sessions

Linkin e-mail Website

Bio

Gaurav Mehra joined Kaizen in 2015 and leads the fund’s Education Technology investments. Prior to joining Kaizen, he co-founded Saba and helped build it into a $150 million public company and a global leader in Talent Management software solutions. With 25 years in building technology and scaling global product and service operations, Gaurav helps portfolio companies shape defensible growth strategies. Gaurav holds BS and MS degrees in Computer Science from Stanford University. As a Partner with Kaizen, an Education, EdTech and HCM focused fund, I evaluate deals, and work with our portfolio partners on operational and scaling challenges.

Sessions